Experimental Pill Doubles Survival in Pancreatic Cancer
A groundbreaking experimental pill has demonstrated the ability to nearly double survival for patients with metastatic pancreatic cancer, one of the deadliest forms of the disease, according to results from a pivotal Phase 3 clinical trial presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The findings, published simultaneously in the New England Journal of Medicine, mark the first time a targeted therapy has shown such a significant advantage over chemotherapy in this notoriously difficult-to-treat cancer.
A New Weapon Against an “Undruggable” Target
The drug, called daraxonrasib (formerly RMC-6236), is an oral medication developed by Revolution Medicines that targets mutations in the RAS gene family — a driver of cancer growth in more than 90% of pancreatic cancer patients. For decades, the KRAS protein was considered “undruggable” because its smooth surface made it extremely difficult for drugs to bind effectively.
Daraxonrasib overcomes this challenge through a novel tri-complex mechanism. It acts as a “molecular glue,” first binding to a chaperone protein called cyclophilin A, and then attaching to active RAS proteins to block the signaling that drives uncontrolled cancer cell growth. Unlike earlier allele-specific inhibitors, this approach targets multiple RAS mutation subtypes — including G12, G13, and Q61 — giving it broad applicability across the pancreatic cancer patient population.
Landmark Trial Results
The global Phase 3 RASolute 302 trial enrolled 500 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) across North America, Europe, and Asia who had previously received one line of chemotherapy. Patients were randomly assigned to receive either daraxonrasib or a second line of chemotherapy.
According to Dana-Farber Cancer Institute, patients who received daraxonrasib achieved a median overall survival of 13.2 months compared to just 6.7 months for those on chemotherapy — representing a 60% reduction in the risk of death (hazard ratio 0.40, p < 0.0001).
Progression-free survival also improved significantly, with a median of 7.2 months for the daraxonrasib group versus 3.6 months for chemotherapy. The objective response rate — meaning substantial tumor shrinkage or disappearance — was 31.6% for daraxonrasib patients compared to 11.2% for those on chemotherapy. Among patients with RAS G12 mutations, the response rate reached 33.2%.
Expert Reactions: “A Game-Changing Situation”
Oncologists who have spent years treating pancreatic cancer expressed profound optimism about the results.
Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute and principal investigator of the RASolute 302 trial, said the findings mark a turning point. “This is the first RAS inhibitor evaluated in a large, randomized trial for patients with pancreatic cancer, and it demonstrates how important an impact these novel medicines are likely to have on the treatment of the disease,” Wolpin said. He added that “a median survival of more than a year in the second-line setting really does get your attention.”
Dr. Zev Wainberg of the University of California, Los Angeles, a study co-leader, described the results as “a very large step forward” even though the drug does not cure the cancer.
Dr. Rachna Shroff of the University of Arizona Cancer Center, who was not involved in the research, told AP News that she “actually started crying” when she first saw the study results. She was struck by how “patients stayed on this treatment because it was providing durable and meaningful benefit to them.”
Dr. Colin Weekes of Mass General Brigham Cancer Institute called it a “game-changing situation,” declaring: “It’s a new day for pancreas cancer.”
A Patient’s Story: Ben Sasse and the “Miracle Drug”
The drug gained public attention when former U.S. Sen. Ben Sasse (R-NE), diagnosed with stage IV pancreatic cancer in December 2025, credited daraxonrasib as a “miracle drug” on 60 Minutes. According to CBS News, Sasse reported a 76% reduction in tumor volume and significantly less pain since beginning treatment.
Regulatory Momentum and Expanded Access
The FDA has granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation, signaling strong regulatory support. On April 30, 2026, the FDA approved an expanded access (compassionate use) program — just three days after the request was submitted — allowing eligible patients with previously treated metastatic pancreatic cancer to receive the drug before formal approval. FDA Commissioner Marty Makary said he is “hopeful that today’s action will improve the lives of patients suffering from this disease.”
Managing Side Effects
While daraxonrasib is generally better tolerated than chemotherapy, it is not without challenges. Common side effects include rash (which can be severe), mouth sores (mucositis/stomatitis), nausea, and diarrhea. Dr. Weekes noted that “there is a price to pay for this success,” emphasizing that toxicity requires dedicated management plans, particularly outside academic centers.
What Comes Next
Researchers are already investigating broader applications. The ongoing RASolute 303 trial is evaluating daraxonrasib as a first-line treatment, both alone and in combination with chemotherapy. Scientists will also explore whether tumor shrinkage from the drug might enable more patients to qualify for potentially curative surgery.
Dr. Wolpin said daraxonrasib should become “a new standard of care” for previously treated metastatic pancreatic cancer. “Were this drug to be approved by the FDA,” he stated, “it would mark a dramatic shift in how pancreatic cancer is treated.”
A Turning Point for Pancreatic Cancer
Pancreatic cancer remains among the most lethal malignancies. The American Cancer Society estimates approximately 67,000 new cases will be diagnosed in the U.S. in 2026, with more than 52,000 deaths. The five-year survival rate hovers around 13%. For decades, chemotherapy offered only modest benefit, with second-line treatment providing a median survival of under seven months.
Daraxonrasib represents the culmination of decades of research into the biology of RAS-driven cancers. Its success not only offers new hope for pancreatic cancer patients but also validates the broader multi-selective RAS(ON) inhibitor approach, opening the door for a new class of targeted cancer therapies. As STAT News reported, the results are “unprecedented” — and for a disease that has seen little progress for generations, that is nothing short of remarkable.